PTEN is a protein tyrosine phosphatase that acts as a tumor suppressor, as a lipid phosphatase that dephosphorylates the D3 position of phosphatidylinositol 3,4,5-trisphosphate and as an antagonist of the PI3k/AKT signaling pathway (1-3). PTEN structural domains includes an
N-terminal phosphatase domain, a lipid binding C2 domain and a 50-amino acid C-terminal tail that contains a PDZ biding sequence.Phosphorylation of the tail suppresses the activity of PTEN by controlling its recruitment into the PTEN- associated complex (4).PTEN is phosphorylated in vitro on Threonine 366 and Serine 370 by glycogen synthase kindase 3 (GSK3) and casein kinase 2 (CK2) respectively.Prior phosphorylation of PTEN at Serine 370 by CK2 strongly
increased its phosphorylation at Threonine 366 by GSK3, suggesting that the two may synergize.Generally, phosphorylation in the C-terminal tail of PTEN is thought to enhance stability and to decrease membrane localization and activity.However, phosphorylation at Threonine 366 is linked to destabilization of PTEN (5).
Applications:
Suitable for use in Western Blot, Immunoprecipitation, Immunohistochemistry and Immunocytochemistry. Other applications not tested.
Recommended Dilution:
Western Blot: 1:10,000-1:20,000
Immunoprecipitation: 1:50
Immunohistochemistry: 1:100-1:250
Immunocytochemistry: 1:100-1:250
Optimal dilutions to be determined by the researcher.
Storage and Stability:
May be stored at 4 degrees C for short-term only. For long-term storage, aliquot and store at -20 degrees C. Aliquots are stable for at least 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Manufactured incorporating RabMAb(R) technology under Epitomics US patents, No 5,675,063 and 7,429,487, owned by Abcam.